People | January 21, 2022
DefiniGen promotes Dr Chris Kirton to CEO
The appointment is key for DefiniGEN as they expand the service portfolio to encompass compound screening
The appointment is key for DefiniGEN as they expand the service portfolio to encompass compound screening
Phase 1/2 trial of E-602 expected to open in Q1 2022 in patients with solid tumours
Quviviq is a dual orexin receptor antagonist, which blocks the binding of the wake-promoting neuropeptides orexins and is thought to turn down overactive wakefulness, as opposed to treatments that generally sedate the brain
Biocon has reported consolidated financial results for the period ended December 31, 2021
The company will receive an upfront payment as well as regulatory and sales based milestone payments from Lotus
Ram’s appointment follows the launch of the CDI India division in October 2021.
However, these won’t be available at the nearest chemist store soon
Unlike most data analysis services, Dolomite Bio will accept sample sizes ranging from as little as one sample, to as many as the research project requires
Nuvaxovid is the first protein-based Covid-19 vaccine to receive approval for provisional registration in Australia
Vigabatrin is an anticonvulsant. It is known to work by stopping the breakdown of a natural calming substance (GABA) in the brain
Subscribe To Our Newsletter & Stay Updated
